At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
etonogestrel implant +1 moredrug
Likely dose
depot medroxyprogesterone acetate 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women
In Brief
A clinical study evaluating etonogestrel implant and depot medroxyprogesterone acetate for Breastfeeding and Contraception. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study to assess the safety of the etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate puerperium of healthy women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreastfeeding, Contraception
CountriesBrazil
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
Primary CompletionFeb 2008
First PostedJan 2009
TodayJul 2026
First PostedJan 26, 2009
Enrollment StartJul 1, 2007
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.4 years ago
Interventions
etonogestrel implantdrug
Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)
depot medroxyprogesterone acetatedrug
150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery